Published in Ann Transl Med on April 01, 2015
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | NCT01829971
Integrative microRNA and gene profiling data analysis reveals novel biomarkers and mechanisms for lung cancer. Oncotarget (2016) 0.87
The Impact of Neuroimmune Alterations in Autism Spectrum Disorder. Front Psychiatry (2015) 0.86
Oncogenic miR-137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma. Am J Cancer Res (2016) 0.77
Genetic and epigenetic silencing of mircoRNA-506-3p enhances COTL1 oncogene expression to foster non-small lung cancer progression. Oncotarget (2016) 0.75
EPHX1 rs2234922 polymorphism and lung cancer susceptibility in Asian populations: a meta-analysis. J Thorac Dis (2015) 0.75
Modification of tumor cell exosome content by transfection with wt-p53 and microRNA-125b expressing plasmid DNA and its effect on macrophage polarization. Oncogenesis (2016) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res (2008) 20.59
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
Lung cancer. N Engl J Med (2008) 13.49
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol (2010) 5.92
MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell (2008) 5.34
miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell (2009) 4.48
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle (2008) 4.35
Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell (2010) 3.72
MicroRNAs in cancer. Annu Rev Pathol (2013) 3.50
Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol (1999) 3.47
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res (2010) 3.21
miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet (2012) 2.89
Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood (2007) 2.83
MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta (2010) 2.55
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med (2011) 2.46
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene (2008) 2.44
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis (2009) 2.41
MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem (2008) 2.28
Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol (2009) 2.10
SnapShot: MicroRNAs in Cancer. Cell (2009) 2.10
Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer (2011) 2.02
Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest (1998) 2.02
miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet (2010) 1.97
Invasive growth: from development to metastasis. J Clin Invest (2002) 1.91
MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle (2011) 1.89
Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res (1998) 1.83
MicroRNAs impair MET-mediated invasive growth. Cancer Res (2008) 1.81
Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer (2011) 1.74
Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol (2011) 1.73
MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets (2012) 1.68
The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J (1994) 1.68
A microRNA guide for clinicians and basic scientists: background and experimental techniques. Heart Lung Circ (2011) 1.60
miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene (2011) 1.58
Meta-analysis of microRNA expression in lung cancer. Int J Cancer (2012) 1.54
Small RNA combination therapy for lung cancer. Proc Natl Acad Sci U S A (2014) 1.43
Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene (2007) 1.42
Technical variables in high-throughput miRNA expression profiling: much work remains to be done. Biochim Biophys Acta (2008) 1.36
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One (2012) 1.32
A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev (2014) 1.31
A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene (2014) 1.29
The p53/miR-34 axis in development and disease. J Mol Cell Biol (2014) 1.28
Met acts on Mdm2 via mTOR to signal cell survival during development. Development (2007) 1.25
Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci U S A (2013) 1.24
miR-30 family members negatively regulate osteoblast differentiation. J Biol Chem (2012) 1.22
miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene (2014) 1.15
Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemother Pharmacol (2006) 1.15
MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One (2013) 1.12
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res (2014) 1.08
Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ (2011) 1.05
MicroRNA-27a promotes proliferation and suppresses apoptosis by targeting PLK2 in laryngeal carcinoma. BMC Cancer (2014) 1.01
Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and Smad2. PLoS One (2014) 0.99
Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PLoS One (2014) 0.99
MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells. Cell Physiol Biochem (2014) 0.97
Down-regulation of miR-203 induced by Helicobacter pylori infection promotes the proliferation and invasion of gastric cancer by targeting CASK. Oncotarget (2014) 0.97
MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett (2014) 0.96
Role of microRNA-1 in human cancer and its therapeutic potentials. Biomed Res Int (2014) 0.90
MiR-199a regulates cell proliferation and survival by targeting FZD7. PLoS One (2014) 0.89
MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int J Oncol (2013) 0.88
miR-199a-5p regulates the expression of metastasis-associated genes in B16F10 melanoma cells. Int J Clin Exp Pathol (2014) 0.86
MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev (2014) 0.83
MicroRNA-409-3p functions as a tumor suppressor in human lung adenocarcinoma by targeting c-Met. Cell Physiol Biochem (2014) 0.83
PKCε acts as negative allosteric modulator of EGF receptor signalling. Cell Signal (2010) 0.83
miR-103 promotes 3T3-L1 cell adipogenesis through AKT/mTOR signal pathway with its target being MEF2D. Biol Chem (2015) 0.83
Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer. Cancer Genet (2014) 0.83
MiRNAs as new master players. Cell Cycle (2009) 0.82
TNFα-induced miR-130 resulted in adipocyte dysfunction during obesity-related inflammation. FEBS Lett (2013) 0.82
The novel miR-7515 decreases the proliferation and migration of human lung cancer cells by targeting c-Met. Mol Cancer Res (2012) 0.80